相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Simple and Highly Sensitive Naked-Eye Analysis of EGFR 19del via CRISPR/Cas12a Triggered No-Nonspecific Nucleic Acid Amplification
Chunfeng Feng et al.
ACS SYNTHETIC BIOLOGY (2022)
SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells
Hideki Terai et al.
MOLECULAR CANCER RESEARCH (2021)
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
Mu-Yang Huang et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Robot-Assisted Thoracic Surgery in Non-small Cell Lung Cancer
Jun Hee Lee et al.
Journal of Chest Surgery (2021)
CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries
K. Sreedurgalakshmi et al.
CANCER GENE THERAPY (2021)
Long-term and short-term outcomes of robot- versus video-assisted anatomic lung resection in lung cancer: a systematic review and meta-analysis
Han Wu et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2021)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer
Dominic Leiser et al.
PLOS ONE (2021)
Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis
Jianglei Ma et al.
BMC CANCER (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M. Reck et al.
ESMO OPEN (2021)
Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
Ziran Zhao et al.
TARGETED ONCOLOGY (2021)
Dose and fractionation schedules in radiotherapy for non-small cell lung cancer
Lucyna Kepka et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
A review on engineered magnetic nanoparticles in Non-Small-Cell lung carcinoma targeted therapy
Lindokuhle M. Ngema et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC
Ha-Ram Park et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Julia Judd et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Ferdinandos Skoulidis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Ravi Salgia et al.
CELL REPORTS MEDICINE (2021)
Video-assisted versus open thoracotomy lobectomy: comparison on lymphadenectomy and survival in early stage of lung cancer
Dariusz A. Dziedzic et al.
JOURNAL OF THORACIC DISEASE (2021)
Epidemiology of lung cancer
Krishna Chaitanya Thandra et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2021)
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis
Chengdi Wang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors
Elisa Caiola et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib
Yiting Li et al.
CANCER (2020)
ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium
Justine Munsterberg et al.
NEURO-ONCOLOGY (2020)
MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer
Xin Tong et al.
ONCOGENE (2020)
Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
Yoshinori Tsukumo et al.
PLOS ONE (2020)
CRISPR-Cas12a: Functional overview and applications
Bijoya Paul et al.
BIOMEDICAL JOURNAL (2020)
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
You Lu et al.
NATURE MEDICINE (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
Xiao-hui Jia et al.
LUNG CANCER (2020)
Improved EGFR mutation detection sensitivity after enrichment by Cas9/sgRNA digestion and PCR amplification
Li Wang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2020)
First line Immunotherapy for Non-Small Cell Lung Cancer
Nicola J. Nasser et al.
PHARMACEUTICALS (2020)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
Kristine Raaby Gammelgaard et al.
TRANSLATIONAL ONCOLOGY (2019)
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
A. T. Shaw et al.
ANNALS OF ONCOLOGY (2019)
Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer
Anubhab Mukherjee et al.
CANCERS (2019)
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib
Irati Garmendia et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Sana Raoof et al.
ONCOGENE (2019)
Compare the prognosis of Da Vinci robot-assisted thoracic surgery (RATS) with video-assisted thoracic surgery (VATS) for non-small cell lung cancer A Meta-analysis
Feng Guo et al.
MEDICINE (2019)
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial
D. Moro-Sibilot et al.
ANNALS OF ONCOLOGY (2019)
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Ana C. Z. Gelatti et al.
LUNG CANCER (2019)
Video-assisted thoracoscopic surgery versus muscle-sparing thoracotomy for non-small cell lung cancer: a systematic review and meta-analysis
Zihuai Wang et al.
BMC SURGERY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells
Eloy Moreno Roig et al.
CELLS (2019)
Targeting BRAF mutations in non-small cell lung cancer
Connor Gerard O'Leary et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
Liliang Xia et al.
ONCOLOGIST (2019)
Radiotherapy in Lung Cancer: Current and Future Role
Esengul Kocak Uzel et al.
MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL (2019)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc'h et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
ALK-rearrangement in non-small-cell lung cancer (NSCLC)
Xue Du et al.
THORACIC CANCER (2018)
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer Benefits and Pulmonary Toxicities
Karthik Suresh et al.
CHEST (2018)
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D. R. Camidge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Comprehensive Review
Daniel J. Tandberg et al.
CANCER (2018)
Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives
Elysia K. Donovan et al.
LUNG CANCER-TARGETS AND THERAPY (2018)
Driven by by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer
Emily Castellanos et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: FromMolecular Profiling to Rationally Designed Therapy
Christina S. Baik et al.
ONCOLOGIST (2017)
ALK and ROS 1 concurrent with EGFR mutation in patients with lung adenocarcinoma
Yanjiao Mao et al.
ONCOTARGETS AND THERAPY (2017)
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
Dianna Hussmann et al.
ONCOTARGET (2017)
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients. Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
Frederic Dugay et al.
ONCOTARGET (2017)
Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
Jinrong Liao et al.
SCIENTIFIC REPORTS (2017)
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
James Luke Godwin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Lung Cancer: Understanding its Molecular Pathology and the 2015 WHO Classification
Kentaro Inamura
FRONTIERS IN ONCOLOGY (2017)
ALK: a tyrosine kinase target for cancer therapy
Vijaykumar R. Holla et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
Paul Zarogoulidis et al.
RESPIRATORY MEDICINE CASE REPORTS (2017)
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Ke-Jing Tang et al.
CLINICAL CANCER RESEARCH (2016)
Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling
Hui Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients
Jeremy M. Kilburn et al.
PRACTICAL RADIATION ONCOLOGY (2016)
Epigenetics in lung cancer diagnosis and therapy
Aditi Mehta et al.
CANCER AND METASTASIS REVIEWS (2015)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Gregory A. Masters et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epigenetics of lung cancer
Scott M. Langevin et al.
TRANSLATIONAL RESEARCH (2015)
Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
Kate McKeage
DRUGS (2015)
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
Heyan Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
Bilal Piperdi et al.
DRUGS (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
CRISPR-Cas systems for editing, regulating and targeting genomes
Jeffry D. Sander et al.
NATURE BIOTECHNOLOGY (2014)
Maintenance Chemotherapy for Advanced Non-Small-Cell Lung Cancer: New Life for an Old Idea
David E. Gerber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
RNA-guided genetic silencing systems in bacteria and archaea
Blake Wiedenheft et al.
NATURE (2012)
Tumor Endothelial Cells
Andrew C. Dudley
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Targeted Therapies for Lung Cancer Clinical Experience and Novel Agents
Jill E. Larsen et al.
CANCER JOURNAL (2011)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
Respiratory Gating Techniques for Optimization of Lung Cancer Radiotherapy
Philippe Giraud et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Marja Lohela et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis
Barbara Bonnesen et al.
LUNG CANCER (2009)
Image-guided radiation therapy for non-small cell lung cancer
Joe Y. Chang et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: results of a multicentre randomized phase II trial
D. Binder et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy:: A multicenter, randomized, phase II trial
Cesare Gridelli et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: A review of the literature
Francesco Grossi et al.
ONCOLOGIST (2007)
Molecular and functional diversity of vascular endothelial growth factors
Yasuo Yamazaki et al.
MOLECULAR DIVERSITY (2006)
Vascular endothelial growth factor signaling pathways: Therapeutic perspective
Marcin Kowanetz et al.
CLINICAL CANCER RESEARCH (2006)
The role of VEGF receptors in angiogenesis;: complex partnerships
S Cébe-Suarez et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer
D Aguiar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer
A Chiappori et al.
ONCOLOGY (2005)
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
C Gridelli et al.
ANNALS OF ONCOLOGY (2004)
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva
P Hamrah et al.
EXPERIMENTAL EYE RESEARCH (2004)
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001)
F Grossi et al.
LUNG CANCER (2004)
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel
MJ Edelman et al.
CLINICAL CANCER RESEARCH (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
S Hosoe et al.
BRITISH JOURNAL OF CANCER (2003)
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma -: Carboplatin and gemcitabine followed by paclitaxel
J De Castro et al.
CANCER (2002)
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer
JI Clark et al.
LUNG CANCER (2001)
Mechanisms of angiogenesis and arteriogenesis
P Carmeliet
NATURE MEDICINE (2000)
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer
K Mattson et al.
ANTI-CANCER DRUGS (2000)
分享论文
